A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis

Clinical trial NCT07663331 · RECRUITING

Trial details

NCT number: NCT07663331
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status: RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Adult Non-infectious Uveitis

Start date: 2026-07-14
Primary completion: 2028-02-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.